BTX-A51

A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
80 patients (estimated)
Sponsors
Edgewood Oncology, Inc.
Tags
CK1-Alpha Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1527
NCT Identifier
NCT04243785

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.